Free Newsletter
U.S. hatches $265M regenerative medicine initiative
The U.S. government is creating a $265 million research initiative that will develop new stem cell technology to re-grow the skin, limbs and muscles of soldiers injured in Iraq and Afghanistan. And those advances in turn will be made available to the people burned and maimed in everyday accidents.
The Armed Forces Institute of Regenerative Medicine will be made up of two multi-institutional consortia, one led by Wake Forest University, Winston-Salem, NC, and the University of Pittsburgh; and one led by Rutgers University, New Brunswick, NJ, and the Cleveland Clinic. The U.S. Army Institute of Surgical Research in San Antonio, Texas, will work with these groups to conduct trials of new therapies. The government is contributing $85 million in defense funding, with an additional $180 million from academic institutions, industry and state and federal agencies.
"Therapies developed by the AFIRM project will greatly benefit wounded warriors, as well as the civilian population with, burns or severe trauma due to illness or injury," said Dr. S. Ward Casscells, assistant secretary of defense for health affairs. The new institute caused at least one company--Intercytex--to boast that it was the only U.K. company to make the cut in an otherwise all-U.S. group of players. Intercytex shares were boosted by the news.
- read the press release
- check out the report in Crain's Manchester Business
Related Articles:
Tissue regeneration a success with new heart
New type of cells developed for tissue repair
Researchers spin living nanothreads for repair work
Genetic machinery remains for limb regeneration
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact




